BenzingaAugust 14, 2026 at 12:12 PM NY21 days ago

Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55

Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story